Traws Pharma (NASDAQ:TRAW) Trading at $0.50

Traws Pharma, Inc. (NASDAQ:TRAW) shares shot up 0% on Tuesday. The company traded as high as $0.5175 and last traded at $0.50. Approximately 109,109 shares changed hands during mid-day trading, an increase of 40% from the average session volume of 78,149 shares. The stock had previously closed at $0.4998.

Analysts Set New Price Targets

TRAW has been the topic of several recent analyst reports. Citigroup lowered shares of Traws Pharma to a “neutral” rating in a research note on Monday, June 15th. HC Wainwright restated a “neutral” rating and issued a $1.00 price target on shares of Traws Pharma in a research note on Tuesday, August 18th. Wall Street Zen raised Traws Pharma from a “strong sell” rating to a “sell” rating in a report on Saturday, June 13th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Traws Pharma in a research report on Wednesday, August 26th. Finally, LADENBURG THALM/SH SH downgraded Traws Pharma from a “buy” rating to a “neutral” rating in a research note on Monday, June 15th. Four investment analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Traws Pharma presently has an average rating of “Reduce” and an average price target of $1.00.

Traws Pharma Stock Up 11.2%

The firm has a market cap of $8.61 million, a price-to-earnings ratio of -0.32 and a beta of 1.60. The company’s 50-day moving average price is $0.54 and its 200-day moving average price is $1.10.

Traws Pharma (NASDAQ:TRAW) last released its quarterly earnings results on Friday, August 14th. The company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.34) by $0.18. Analysts predict that Traws Pharma, Inc. will post -1.2 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Traws Pharma

A hedge fund recently bought a new position in Traws Pharma stock. Seven Fleet Capital Management LP bought a new position in shares of Traws Pharma, Inc. (NASDAQ:TRAW) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 49,260 shares of the company’s stock, valued at approximately $56,000. Seven Fleet Capital Management LP owned about 0.62% of Traws Pharma at the end of the most recent reporting period. 7.95% of the stock is owned by hedge funds and other institutional investors.

Traws Pharma Company Profile

Traws Pharma, Inc (NASDAQ: TRAW) is a clinical-stage biopharmaceutical company developing therapies for respiratory viral infections and cancer. The company’s programs are focused on addressing diseases with significant unmet medical needs, and its candidates remain in clinical development rather than being marketed as approved products.

Traws Pharma’s antiviral portfolio includes tivoxavir marboxil, an investigational oral treatment designed to inhibit the influenza virus cap-dependent endonuclease and potentially treat influenza A and B infections.